{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T11:06:50Z","timestamp":1781176010021,"version":"3.54.1"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T00:00:00Z","timestamp":1663804800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T00:00:00Z","timestamp":1663804800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["HV20C0139"],"award-info":[{"award-number":["HV20C0139"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003569","name":"Ministry of Food and Drug Safety","doi-asserted-by":"publisher","award":["22202MFDS173"],"award-info":[{"award-number":["22202MFDS173"]}],"id":[{"id":"10.13039\/501100003569","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Previously, we reported that a hygromycin resistant version of the BCG\u0394BCG1419c vaccine candidate reduced tuberculosis (TB) disease in BALB\/c, C57BL\/6, and B6D2F1 mice infected with <jats:italic>Mycobacterium tuberculosis<\/jats:italic> (Mtb) H37Rv. Here, the second-generation version of BCG\u0394BCG1419c (based on BCG Pasteur ATCC 35734, without antibiotic resistance markers, and a complete deletion of <jats:italic>BCG1419c<\/jats:italic>) was compared to its parental BCG for immunogenicity and protective efficacy against the Mtb clinical isolate M2 in C57BL\/6 mice. Both BCG and BCG\u0394BCG1419c induced production of IFN-\u03b3, TNF-\u03b1, and\/or IL-2 by effector memory (CD44<jats:sup>+<\/jats:sup>CD62L<jats:sup>\u2212<\/jats:sup>), PPD-specific, CD4<jats:sup>+<\/jats:sup> T cells, and only BCG\u0394BCG1419c increased effector memory, PPD-specific CD8<jats:sup>+<\/jats:sup> T cell responses in the lungs and spleens compared with unvaccinated mice before challenge. BCG\u0394BCG1419c increased levels of central memory (CD62L<jats:sup>+<\/jats:sup>CD44<jats:sup>+<\/jats:sup>) T CD4<jats:sup>+<\/jats:sup> and CD8<jats:sup>+<\/jats:sup> cells compared to those of BCG-vaccinated mice. Both BCG strains elicited Th1-biased antigen-specific polyfunctional effector memory CD4<jats:sup>+<\/jats:sup>\/CD8<jats:sup>+<\/jats:sup> T cell responses at 10\u00a0weeks post-infection, and both vaccines controlled Mtb M2 growth in the lung and spleen. Only BCG\u0394BCG1419c significantly ameliorated pulmonary inflammation and decreased neutrophil infiltration into the lung compared to BCG-vaccinated and unvaccinated mice. Both BCG strains reduced pulmonary TNF-\u03b1, IFN-\u03b3, and IL-10 levels. Taken together, BCG\u0394BCG1419c increased memory CD8+T cell-associated immunogenicity and mitigated pulmonary inflammation compared with BCG.<\/jats:p>","DOI":"10.1038\/s41598-022-20017-w","type":"journal-article","created":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T16:12:59Z","timestamp":1663863179000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["BCG\u0394BCG1419c increased memory CD8+ T cell-associated immunogenicity and mitigated pulmonary inflammation compared with BCG in a model of chronic tuberculosis"],"prefix":"10.1038","volume":"12","author":[{"given":"Kee Woong","family":"Kwon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel de Jes\u00fas","family":"Aceves-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian Alfredo","family":"Segura-Cerda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunsol","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helle","family":"Bielefeldt-Ohmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Jae","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario Alberto","family":"Flores-Valdez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,22]]},"reference":[{"issue":"Suppl 1","key":"20017_CR1","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1016\/j.ijid.2021.02.107","volume":"113","author":"J Chakaya","year":"2021","unstructured":"Chakaya, J. et al. Global tuberculosis report 2020\u2014REFLECTIONS ON THE Global TB burden, treatment and prevention efforts. Int. J. Infect. Dis. 113(Suppl 1), S7\u2013S12. https:\/\/doi.org\/10.1016\/j.ijid.2021.02.107 (2021).","journal-title":"Int. J. Infect. Dis."},{"key":"20017_CR2","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/s41467-020-20731-x","volume":"12","author":"H Fu","year":"2021","unstructured":"Fu, H., Lewnard, J. A., Frost, I., Laxminarayan, R. & Arinaminpathy, N. Modelling the global burden of drug-resistant tuberculosis avertable by a post-exposure vaccine. Nat. Commun. 12, 424. https:\/\/doi.org\/10.1038\/s41467-020-20731-x (2021).","journal-title":"Nat. Commun."},{"key":"20017_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fcimb.2019.00342","volume":"9","author":"CA Segura-Cerda","year":"2019","unstructured":"Segura-Cerda, C. A., L\u00f3pez-Romero, W. & Flores-Valdez, M. A. Changes in host response to Mycobacterium tuberculosis infection associated with type 2 diabetes: Beyond hyperglycemia. Front. Cell. Infect. Microbiol. 9, 1\u201310. https:\/\/doi.org\/10.3389\/fcimb.2019.00342 (2019).","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"20017_CR4","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.1016\/S1473-3099(19)30625-5","volume":"20","author":"LK Schrager","year":"2020","unstructured":"Schrager, L. K., Vekemens, J., Drager, N., Lewinsohn, D. M. & Olesen, O. F. The status of tuberculosis vaccine development. Lancet Infect. Dis. 20, e28\u2013e37. https:\/\/doi.org\/10.1016\/S1473-3099(19)30625-5 (2020).","journal-title":"Lancet Infect. Dis."},{"key":"20017_CR5","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41541-021-00343-2","volume":"6","author":"M Coppola","year":"2021","unstructured":"Coppola, M. et al. In-vivo expressed Mycobacterium tuberculosis antigens recognised in three mouse strains after infection and BCG vaccination. NPJ Vaccines 6, 81. https:\/\/doi.org\/10.1038\/s41541-021-00343-2 (2021).","journal-title":"NPJ Vaccines"},{"key":"20017_CR6","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.smim.2018.07.001","volume":"39","author":"M Coppola","year":"2018","unstructured":"Coppola, M. & Ottenhoff, T. H. Genome wide approaches discover novel Mycobacterium tuberculosis antigens as correlates of infection, disease, immunity and targets for vaccination. Semin. Immunol. 39, 88\u2013101. https:\/\/doi.org\/10.1016\/j.smim.2018.07.001 (2018).","journal-title":"Semin. Immunol."},{"key":"20017_CR7","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3389\/fimmu.2020.00103","volume":"11","author":"M Coppola","year":"2020","unstructured":"Coppola, M. et al. Cell-mediated immune responses to in vivo-expressed and stage-specific Mycobacterium tuberculosis antigens in latent and active tuberculosis across different age groups. Front. Immunol. 11, 103. https:\/\/doi.org\/10.3389\/fimmu.2020.00103 (2020).","journal-title":"Front. Immunol."},{"key":"20017_CR8","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3389\/fimmu.2018.00121","volume":"9","author":"NE Nieuwenhuizen","year":"2018","unstructured":"Nieuwenhuizen, N. E. & Kaufmann, S. H. E. Next-generation vaccines based on Bacille Calmette-Guerin. Front. Immunol. 9, 121. https:\/\/doi.org\/10.3389\/fimmu.2018.00121 (2018).","journal-title":"Front. Immunol."},{"key":"20017_CR9","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1016\/j.vaccine.2012.12.053","volume":"31","author":"L Grode","year":"2013","unstructured":"Grode, L. et al. Safety and immunogenicity of the recombinant BCG vaccine VPM1002 in a phase 1 open-label randomized clinical trial. Vaccine 31, 1340\u20131348. https:\/\/doi.org\/10.1016\/j.vaccine.2012.12.053 (2013).","journal-title":"Vaccine"},{"key":"20017_CR10","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1128\/CVI.00439-16","volume":"24","author":"AG Loxton","year":"2017","unstructured":"Loxton, A. G. et al. Safety and Immunogenicity of the Recombinant Mycobacterium bovis BCG Vaccine VPM1002 in HIV-Unexposed Newborn Infants in South Africa. Clin Vaccine Immunol 24, 5. https:\/\/doi.org\/10.1128\/CVI.00439-16 (2017).","journal-title":"Clin Vaccine Immunol"},{"key":"20017_CR11","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/S2213-2600(15)00435-X","volume":"3","author":"F Spertini","year":"2015","unstructured":"Spertini, F. et al. Safety of human immunisation with a live-attenuated Mycobacterium tuberculosis vaccine: A randomised, double-blind, controlled phase I trial. Lancet Respir. Med. 3, 953\u2013962. https:\/\/doi.org\/10.1016\/S2213-2600(15)00435-X (2015).","journal-title":"Lancet Respir. Med."},{"key":"20017_CR12","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S2213-2600(19)30251-6","volume":"7","author":"M Tameris","year":"2019","unstructured":"Tameris, M. et al. Live-attenuated Mycobacterium tuberculosis vaccine MTBVAC versus BCG in adults and neonates: A randomised controlled, double-blind dose-escalation trial. Lancet Respir. Med. 7, 757\u2013770. https:\/\/doi.org\/10.1016\/S2213-2600(19)30251-6 (2019).","journal-title":"Lancet Respir. Med."},{"key":"20017_CR13","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/iub.1353","volume":"67","author":"MA Flores-Valdez","year":"2015","unstructured":"Flores-Valdez, M. A. et al. The cyclic Di-GMP phosphodiesterase gene Rv1357c\/BCG1419c affects BCG pellicle production and in vivo maintenance. IUBMB Life 67, 129\u2013138. https:\/\/doi.org\/10.1002\/iub.1353 (2015).","journal-title":"IUBMB Life"},{"key":"20017_CR14","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3389\/fmicb.2016.00014","volume":"7","author":"MA Flores-Valdez","year":"2016","unstructured":"Flores-Valdez, M. A. Vaccines directed against microorganisms or their products present during biofilm lifestyle: Can we make a translation as a broad biological model to tuberculosis?. Front. Microbiol. 7, 14. https:\/\/doi.org\/10.3389\/fmicb.2016.00014 (2016).","journal-title":"Front. Microbiol."},{"key":"20017_CR15","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1038\/s41467-021-21748-6","volume":"12","author":"P Chakraborty","year":"2021","unstructured":"Chakraborty, P., Bajeli, S., Kaushal, D., Radotra, B. D. & Kumar, A. Biofilm formation in the lung contributes to virulence and drug tolerance of Mycobacterium tuberculosis. Nat. Commun. 12, 1606. https:\/\/doi.org\/10.1038\/s41467-021-21748-6 (2021).","journal-title":"Nat. Commun."},{"key":"20017_CR16","doi-asserted-by":"publisher","first-page":"102153","DOI":"10.1016\/j.tube.2021.102153","volume":"132","author":"J Bacon","year":"2021","unstructured":"Bacon, J., Waddell, S. J. & Flores-Valdez, M. A. Biofilms in tuberculosis: What have we learnt in the past decade and what is still unexplored?. Tuberculosis (Edinb.) 132, 102153. https:\/\/doi.org\/10.1016\/j.tube.2021.102153 (2021).","journal-title":"Tuberculosis (Edinb.)"},{"key":"20017_CR17","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1038\/s42003-021-02769-9","volume":"4","author":"A Kolloli","year":"2021","unstructured":"Kolloli, A. et al. Aggregation state of Mycobacterium tuberculosis impacts host immunity and augments pulmonary disease pathology. Commun. Biol. 4, 1256. https:\/\/doi.org\/10.1038\/s42003-021-02769-9 (2021).","journal-title":"Commun. Biol."},{"key":"20017_CR18","doi-asserted-by":"publisher","first-page":"4763","DOI":"10.1016\/j.vaccine.2016.08.035","volume":"34","author":"C Pedroza-Roldan","year":"2016","unstructured":"Pedroza-Roldan, C. et al. The BCGDeltaBCG1419c strain, which produces more pellicle in vitro, improves control of chronic tuberculosis in vivo. Vaccine 34, 4763\u20134770. https:\/\/doi.org\/10.1016\/j.vaccine.2016.08.035 (2016).","journal-title":"Vaccine"},{"key":"20017_CR19","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.3389\/fmicb.2018.01281","volume":"9","author":"MA Flores-Valdez","year":"2018","unstructured":"Flores-Valdez, M. A. et al. The BCGDeltaBCG1419c vaccine candidate reduces lung pathology, IL-6, TNF-alpha, and IL-10 during chronic TB infection. Front. Microbiol. 9, 1281. https:\/\/doi.org\/10.3389\/fmicb.2018.01281 (2018).","journal-title":"Front. Microbiol."},{"key":"20017_CR20","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41541-020-00250-y","volume":"5","author":"CA Segura-Cerda","year":"2020","unstructured":"Segura-Cerda, C. A. et al. Erratum: Author Correction: BCG and BCG\u0394BCG1419c protect type 2 diabetic mice against tuberculosis via different participation of T and B lymphocytes, dendritic cells and pro-inflammatory cytokines. NPJ Vaccines 5, 100. https:\/\/doi.org\/10.1038\/s41541-020-00250-y (2020).","journal-title":"NPJ Vaccines"},{"key":"20017_CR21","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1016\/j.vaccine.2018.03.014","volume":"36","author":"CA Segura-Cerda","year":"2018","unstructured":"Segura-Cerda, C. A. et al. Immune response elicited by two rBCG strains devoid of genes involved in c-di-GMP metabolism affect protection versus challenge with M. tuberculosis strains of different virulence. Vaccine 36, 2069\u20132078. https:\/\/doi.org\/10.1016\/j.vaccine.2018.03.014 (2018).","journal-title":"Vaccine"},{"key":"20017_CR22","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1093\/femspd\/ftaa070","volume":"79","author":"JB Velazquez-Fernandez","year":"2021","unstructured":"Velazquez-Fernandez, J. B. et al. Proteomic characterization of a second-generation version of the BCGDeltaBCG1419c vaccine candidate by means of electrospray-ionization quadrupole time-of-flight mass spectrometry. Pathog. Dis. 79, 5. https:\/\/doi.org\/10.1093\/femspd\/ftaa070 (2021).","journal-title":"Pathog. Dis."},{"key":"20017_CR23","doi-asserted-by":"publisher","first-page":"12417","DOI":"10.1038\/s41598-021-91993-8","volume":"11","author":"MJ Aceves-Sanchez","year":"2021","unstructured":"Aceves-Sanchez, M. J. et al. Vaccination with BCGDeltaBCG1419c protects against pulmonary and extrapulmonary TB and is safer than BCG. Sci. Rep. 11, 12417. https:\/\/doi.org\/10.1038\/s41598-021-91993-8 (2021).","journal-title":"Sci. Rep."},{"key":"20017_CR24","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.vaccine.2020.11.073","volume":"39","author":"MA Flores-Valdez","year":"2021","unstructured":"Flores-Valdez, M. A. & Segura-Cerda, C. A. Preclinical evaluation of tuberculosis vaccine candidates: Is it time to harmonize study design and readouts for prioritizing their development?. Vaccine 39, 173\u2013175. https:\/\/doi.org\/10.1016\/j.vaccine.2020.11.073 (2021).","journal-title":"Vaccine"},{"key":"20017_CR25","doi-asserted-by":"publisher","first-page":"44151","DOI":"10.1038\/srep44151","volume":"7","author":"KW Kwon","year":"2017","unstructured":"Kwon, K. W. et al. Novel vaccine potential of Rv3131, a DosR regulon-encoded putative nitroreductase, against hyper-virulent Mycobacterium tuberculosis strain K. Sci. Rep. 7, 44151. https:\/\/doi.org\/10.1038\/srep44151 (2017).","journal-title":"Sci. Rep."},{"key":"20017_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005809","volume":"12","author":"KE Wiens","year":"2016","unstructured":"Wiens, K. E. & Ernst, J. D. The mechanism for type I interferon induction by Mycobacterium tuberculosis is bacterial strain-dependent. PLoS Pathog. 12, e1005809. https:\/\/doi.org\/10.1371\/journal.ppat.1005809 (2016).","journal-title":"PLoS Pathog."},{"key":"20017_CR27","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.tube.2013.11.003","volume":"94","author":"H McShane","year":"2014","unstructured":"McShane, H. & Williams, A. A review of preclinical animal models utilised for TB vaccine evaluation in the context of recent human efficacy data. Tuberculosis (Edinb.) 94, 105\u2013110. https:\/\/doi.org\/10.1016\/j.tube.2013.11.003 (2014).","journal-title":"Tuberculosis (Edinb.)"},{"key":"20017_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0136500","volume":"10","author":"M Henao-Tamayo","year":"2015","unstructured":"Henao-Tamayo, M. et al. The efficacy of the BCG vaccine against newly emerging clinical strains of Mycobacterium tuberculosis. PLoS ONE 10, e0136500. https:\/\/doi.org\/10.1371\/journal.pone.0136500 (2015).","journal-title":"PLoS ONE"},{"key":"20017_CR29","doi-asserted-by":"publisher","first-page":"2472","DOI":"10.1172\/JCI24617","volume":"115","author":"L Grode","year":"2005","unstructured":"Grode, L. et al. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that secrete listeriolysin. J. Clin. Invest. 115, 2472\u20132479. https:\/\/doi.org\/10.1172\/JCI24617 (2005).","journal-title":"J. Clin. Invest."},{"key":"20017_CR30","doi-asserted-by":"publisher","first-page":"5173","DOI":"10.1128\/IAI.00019-08","volume":"76","author":"BY Jeon","year":"2008","unstructured":"Jeon, B. Y. et al. Mycobacterium bovis BCG immunization induces protective immunity against nine different Mycobacterium tuberculosis strains in mice. Infect. Immun. 76, 5173\u20135180. https:\/\/doi.org\/10.1128\/IAI.00019-08 (2008).","journal-title":"Infect. Immun."},{"key":"20017_CR31","doi-asserted-by":"publisher","first-page":"2752","DOI":"10.1016\/j.celrep.2017.02.057","volume":"18","author":"MI Groschel","year":"2017","unstructured":"Groschel, M. I. et al. Recombinant BCG expressing ESX-1 of Mycobacterium marinum combines low virulence with cytosolic immune signaling and improved TB protection. Cell Rep. 18, 2752\u20132765. https:\/\/doi.org\/10.1016\/j.celrep.2017.02.057 (2017).","journal-title":"Cell Rep."},{"key":"20017_CR32","doi-asserted-by":"publisher","first-page":"8047","DOI":"10.4049\/jimmunol.0801592","volume":"182","author":"T Lindenstr\u00f8m","year":"2009","unstructured":"Lindenstr\u00f8m, T. et al. Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells. J. Immunol. 182, 8047\u20138055. https:\/\/doi.org\/10.4049\/jimmunol.0801592 (2009).","journal-title":"J. Immunol."},{"key":"20017_CR33","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.4049\/jimmunol.0900947","volume":"183","author":"CS Aagaard","year":"2009","unstructured":"Aagaard, C. S., Hoang, T. T., Vingsbo-Lundberg, C., Dietrich, J. & Andersen, P. Quality and vaccine efficacy of CD4+ T cell responses directed to dominant and subdominant epitopes in ESAT-6 from Mycobacterium tuberculosis. J. Immunol. 183, 2659\u20132668. https:\/\/doi.org\/10.4049\/jimmunol.0900947 (2009).","journal-title":"J. Immunol."},{"key":"20017_CR34","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1002\/eji.200939754","volume":"40","author":"TJ Scriba","year":"2010","unstructured":"Scriba, T. J. et al. Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells. Eur. J. Immunol. 40, 279\u2013290. https:\/\/doi.org\/10.1002\/eji.200939754 (2010).","journal-title":"Eur. J. Immunol."},{"key":"20017_CR35","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1164\/rccm.200910-1484OC","volume":"181","author":"B Abel","year":"2010","unstructured":"Abel, B. et al. The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults. Am. J. Respir. Crit. Care Med. 181, 1407\u20131417. https:\/\/doi.org\/10.1164\/rccm.200910-1484OC (2010).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"20017_CR36","doi-asserted-by":"publisher","first-page":"3973","DOI":"10.4049\/jimmunol.179.6.3973","volume":"179","author":"R Billeskov","year":"2007","unstructured":"Billeskov, R., Vingsbo-Lundberg, C., Andersen, P. & Dietrich, J. Induction of CD8 T cells against a novel epitope in TB10.4: Correlation with mycobacterial virulence and the presence of a functional region of difference-1. J. Immunol. 179, 3973\u20133981. https:\/\/doi.org\/10.4049\/jimmunol.179.6.3973 (2007).","journal-title":"J. Immunol."},{"key":"20017_CR37","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1093\/infdis\/jiu347","volume":"210","author":"A Vogelzang","year":"2014","unstructured":"Vogelzang, A. et al. Central memory CD4+ T cells are responsible for the recombinant Bacillus Calmette-Gu\u00e9rin \u0394ureC::hly vaccine\u2019s superior protection against tuberculosis. J. Infect. Dis. 210, 1928\u20131937. https:\/\/doi.org\/10.1093\/infdis\/jiu347 (2014).","journal-title":"J. Infect. Dis."},{"key":"20017_CR38","doi-asserted-by":"publisher","first-page":"16085","DOI":"10.1038\/ncomms16085","volume":"8","author":"N Aguilo","year":"2017","unstructured":"Aguilo, N. et al. Reactogenicity to major tuberculosis antigens absent in BCG is linked to improved protection against Mycobacterium tuberculosis. Nat. Commun. 8, 16085. https:\/\/doi.org\/10.1038\/ncomms16085 (2017).","journal-title":"Nat. Commun."},{"key":"20017_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102761","volume":"55","author":"I Perez","year":"2020","unstructured":"Perez, I. et al. Live attenuated TB vaccines representing the three modern Mycobacterium tuberculosis lineages reveal that the Euro-American genetic background confers optimal vaccine potential. EBioMedicine 55, 102761. https:\/\/doi.org\/10.1016\/j.ebiom.2020.102761 (2020).","journal-title":"EBioMedicine"},{"key":"20017_CR40","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.immuni.2006.04.003","volume":"24","author":"SH Kaufmann","year":"2006","unstructured":"Kaufmann, S. H. Tuberculosis: Back on the immunologists\u2019 agenda. Immunity 24, 351\u2013357. https:\/\/doi.org\/10.1016\/j.immuni.2006.04.003 (2006).","journal-title":"Immunity"},{"key":"20017_CR41","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1146\/annurev.micro.61.080706.093426","volume":"61","author":"R Tamayo","year":"2007","unstructured":"Tamayo, R., Pratt, J. T. & Camilli, A. Roles of cyclic diguanylate in the regulation of bacterial pathogenesis. Annu. Rev. Microbiol. 61, 131\u2013148. https:\/\/doi.org\/10.1146\/annurev.micro.61.080706.093426 (2007).","journal-title":"Annu. Rev. Microbiol."},{"key":"20017_CR42","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3390\/vaccines9080917","volume":"9","author":"H Yan","year":"2021","unstructured":"Yan, H. & Chen, W. The promise and challenges of cyclic dinucleotides as molecular adjuvants for vaccine development. Vaccines (Basel) 9, 9. https:\/\/doi.org\/10.3390\/vaccines9080917 (2021).","journal-title":"Vaccines (Basel)"},{"key":"20017_CR43","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/nature10429","volume":"478","author":"DL Burdette","year":"2011","unstructured":"Burdette, D. L. et al. STING is a direct innate immune sensor of cyclic di-GMP. Nature 478, 515\u2013518. https:\/\/doi.org\/10.1038\/nature10429 (2011).","journal-title":"Nature"},{"key":"20017_CR44","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1084\/jem.20082874","volume":"206","author":"SM McWhirter","year":"2009","unstructured":"McWhirter, S. M. et al. A host type I interferon response is induced by cytosolic sensing of the bacterial second messenger cyclic-di-GMP. J. Exp. Med. 206, 1899\u20131911. https:\/\/doi.org\/10.1084\/jem.20082874 (2009).","journal-title":"J. Exp. Med."},{"key":"20017_CR45","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1126\/science.1244040","volume":"341","author":"XD Li","year":"2013","unstructured":"Li, X. D. et al. Pivotal roles of cGAS-cGAMP signaling in antiviral defense and immune adjuvant effects. Science 341, 1390\u20131394. https:\/\/doi.org\/10.1126\/science.1244040 (2013).","journal-title":"Science"},{"key":"20017_CR46","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1177\/2051013613501988","volume":"1","author":"TW Dubensky Jr","year":"2013","unstructured":"Dubensky, T. W. Jr., Kanne, D. B. & Leong, M. L. Rationale, progress and development of vaccines utilizing STING-activating cyclic dinucleotide adjuvants. Ther. Adv. Vaccines 1, 131\u2013143. https:\/\/doi.org\/10.1177\/2051013613501988 (2013).","journal-title":"Ther. Adv. Vaccines"},{"key":"20017_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109696","volume":"36","author":"YJ Lu","year":"2021","unstructured":"Lu, Y. J. et al. CD4 T cell help prevents CD8 T cell exhaustion and promotes control of Mycobacterium tuberculosis infection. Cell. Rep. 36, 109696. https:\/\/doi.org\/10.1016\/j.celrep.2021.109696 (2021).","journal-title":"Cell. Rep."},{"key":"20017_CR48","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1038\/ni978","volume":"4","author":"A Le Bon","year":"2003","unstructured":"Le Bon, A. et al. Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nat. Immunol. 4, 1009\u20131015. https:\/\/doi.org\/10.1038\/ni978 (2003).","journal-title":"Nat. Immunol."},{"key":"20017_CR49","doi-asserted-by":"publisher","first-page":"16302","DOI":"10.1073\/pnas.0808746105","volume":"105","author":"T Cohen","year":"2008","unstructured":"Cohen, T., Colijn, C. & Murray, M. Modeling the effects of strain diversity and mechanisms of strain competition on the potential performance of new tuberculosis vaccines. Proc. Natl. Acad. Sci. USA 105, 16302\u201316307. https:\/\/doi.org\/10.1073\/pnas.0808746105 (2008).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"20017_CR50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000988","volume":"6","author":"S Homolka","year":"2010","unstructured":"Homolka, S., Niemann, S., Russell, D. G. & Rohde, K. H. Functional genetic diversity among Mycobacterium tuberculosis complex clinical isolates: delineation of conserved core and lineage-specific transcriptomes during intracellular survival. PLoS Pathog. 6, e1000988. https:\/\/doi.org\/10.1371\/journal.ppat.1000988 (2010).","journal-title":"PLoS Pathog."},{"key":"20017_CR51","doi-asserted-by":"publisher","first-page":"3614","DOI":"10.1128\/jcm.00157-10","volume":"48","author":"A Cubillos-Ruiz","year":"2010","unstructured":"Cubillos-Ruiz, A. et al. Genomic signatures of the haarlem lineage of Mycobacterium tuberculosis: Implications of strain genetic variation in drug and vaccine development. J. Clin. Microbiol. 48, 3614\u20133623. https:\/\/doi.org\/10.1128\/jcm.00157-10 (2010).","journal-title":"J. Clin. Microbiol."},{"key":"20017_CR52","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.4049\/jimmunol.1101122","volume":"187","author":"CL Day","year":"2011","unstructured":"Day, C. L. et al. Functional capacity of Mycobacterium tuberculosis-specific T cell responses in humans is associated with mycobacterial load. J. Immunol. 187, 2222\u20132232. https:\/\/doi.org\/10.4049\/jimmunol.1101122 (2011).","journal-title":"J. Immunol."},{"key":"20017_CR53","doi-asserted-by":"publisher","first-page":"4955","DOI":"10.4049\/jimmunol.181.7.4955","volume":"181","author":"EK Forbes","year":"2008","unstructured":"Forbes, E. K. et al. Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice. J. Immunol. 181, 4955\u20134964. https:\/\/doi.org\/10.4049\/jimmunol.181.7.4955 (2008).","journal-title":"J. Immunol."},{"key":"20017_CR54","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1128\/IAI.00685-08","volume":"77","author":"EZ Tchilian","year":"2009","unstructured":"Tchilian, E. Z. et al. Immunogenicity and protective efficacy of prime-boost regimens with recombinant (delta)ureC hly+ Mycobacterium bovis BCG and modified vaccinia virus ankara expressing M. tuberculosis antigen 85A against murine tuberculosis. Infect. Immun. 77, 622\u2013631. https:\/\/doi.org\/10.1128\/IAI.00685-08 (2009).","journal-title":"Infect. Immun."},{"key":"20017_CR55","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/s0140-6736(13)60177-4","volume":"381","author":"MD Tameris","year":"2013","unstructured":"Tameris, M. D. et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: A randomised, placebo-controlled phase 2b trial. Lancet 381, 1021\u20131028. https:\/\/doi.org\/10.1016\/s0140-6736(13)60177-4 (2013).","journal-title":"Lancet"},{"key":"20017_CR56","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1164\/rccm.201003-0334OC","volume":"182","author":"BM Kagina","year":"2010","unstructured":"Kagina, B. M. et al. Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Gu\u00e9rin vaccination of newborns. Am. J. Respir. Crit. Care Med. 182, 1073\u20131079. https:\/\/doi.org\/10.1164\/rccm.201003-0334OC (2010).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"20017_CR57","doi-asserted-by":"publisher","first-page":"17072","DOI":"10.1038\/nmicrobiol.2017.72","volume":"2","author":"BB Mishra","year":"2017","unstructured":"Mishra, B. B. et al. Nitric oxide prevents a pathogen-permissive granulocytic inflammation during tuberculosis. Nat. Microbiol. 2, 17072. https:\/\/doi.org\/10.1038\/nmicrobiol.2017.72 (2017).","journal-title":"Nat. Microbiol."},{"key":"20017_CR58","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/s41385-020-0300-z","volume":"14","author":"RR Lovewell","year":"2021","unstructured":"Lovewell, R. R., Baer, C. E., Mishra, B. B., Smith, C. M. & Sassetti, C. M. Granulocytes act as a niche for Mycobacterium tuberculosis growth. Mucosal Immunol. 14, 229\u2013241. https:\/\/doi.org\/10.1038\/s41385-020-0300-z (2021).","journal-title":"Mucosal Immunol."},{"key":"20017_CR59","doi-asserted-by":"publisher","DOI":"10.1101\/2020.10.21.349373","author":"B Khatri","year":"2020","unstructured":"Khatri, B. et al. Efficacy and immunogenicity of different BCG doses in BALB\/c and CB6F1 mice when challenged with H37Rv or Beijing HN878. bioRxiv https:\/\/doi.org\/10.1101\/2020.10.21.349373 (2020).","journal-title":"bioRxiv"},{"key":"20017_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.08.030","author":"I Heijmenberg","year":"2021","unstructured":"Heijmenberg, I. et al. ESX-5-targeted export of ESAT-6 in BCG combines enhanced immunogenicity & efficacy against murine tuberculosis with low virulence and reduced persistence. Vaccine https:\/\/doi.org\/10.1016\/j.vaccine.2021.08.030 (2021).","journal-title":"Vaccine"},{"key":"20017_CR61","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.592333","volume":"11","author":"A Khan","year":"2020","unstructured":"Khan, A. et al. NOD2\/RIG-I activating inarigivir adjuvant enhances the efficacy of BCG vaccine against tuberculosis in mice. Front. Immunol. 11, 592333. https:\/\/doi.org\/10.3389\/fimmu.2020.592333 (2020).","journal-title":"Front. Immunol."},{"key":"20017_CR62","doi-asserted-by":"publisher","first-page":"15560","DOI":"10.1038\/s41598-019-52146-0","volume":"9","author":"KW Kwon","year":"2019","unstructured":"Kwon, K. W. et al. Long-term protective efficacy with a BCG-prime ID93\/GLA-SE boost regimen against the hyper-virulent Mycobacterium tuberculosis strain K in a mouse model. Sci. Rep. 9, 15560. https:\/\/doi.org\/10.1038\/s41598-019-52146-0 (2019).","journal-title":"Sci. Rep."},{"key":"20017_CR63","doi-asserted-by":"publisher","first-page":"19947","DOI":"10.18632\/oncotarget.15256","volume":"8","author":"HG Choi","year":"2017","unstructured":"Choi, H. G. et al. Rv2299c, a novel dendritic cell-activating antigen of Mycobacterium tuberculosis, fused-ESAT-6 subunit vaccine confers improved and durable protection against the hypervirulent strain HN878 in mice. Oncotarget 8, 19947\u201319967. https:\/\/doi.org\/10.18632\/oncotarget.15256 (2017).","journal-title":"Oncotarget"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-20017-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-20017-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-20017-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T16:33:31Z","timestamp":1663864411000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-20017-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,22]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["20017"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-20017-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,22]]},"assertion":[{"value":"25 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.A.F.V., M.J.A.S. have a patent issued for the BCG\u0394BCG1419c as vaccine candidate against tuberculosis. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15824"}}